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 INTRODUCTION 
 Worldwide, cardiovascular diseases are the greatest 
cause of mortality (1). In 2013, the American Heart 
Association reported that 28 million Americans suﬀ ered 
from cardiovascular diseases and, among these, ﬁ ve 
million had experienced heart failure (HF) (2). HF repre-
sents a growing problem due to general population aging 
and to the prolongation of patients ’ lives as a result of 
improvements in medical treatment and procedures (3). 
From a clinical point of view, it is noteworthy that most 
HF cases can be attributed to modiﬁ able risk factors and, 
consequently, preventable (4). 
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 ABSTRACT 
 Background: The role of cardiovascular risk factor control in the development of heart failure (HF) has not yet been clearly 
established. 
 Objective: To determine the eﬀ ect of cardiovascular risk factor control on the occurrence of a ﬁ rst episode of hospital admission 
for HF. 
 Methods: A case-control study using propensity score-matching was carried out to analyse the occurrence of ﬁ rst hospital admission 
for HF taking into account the degree of cardiovascular risk factor control over the previous 24 months. All patients admitted to the 
cardiology unit of the Hospital del Mar between 2008 and 2011 because of a ﬁ rst episode of HF were considered cases. Controls 
were selected from the population in the hospital catchment area who were using primary care services. Cardiovascular risk factor 
measurements in the primary healthcare electronic medical records prior to the ﬁ rst HF episode were analysed. 
 Results: After the matching process, 645 participants were analysed (129 HF cases and 516 controls). Patients suﬀ ering a ﬁ rst HF 
episode had modest increments in body mass index and blood pressure levels during the previous two years. Adjusted odds ratio 
for experiencing a ﬁ rst HF hospital admission episode according to systolic blood pressure levels and body mass index was (OR: 
1.031, 95% CI: 1.001 – 1.04), and (OR: 1.09, 95% CI: 1.03 – 1.15), respectively. 
 Conclusion : Increased levels of body mass index and systolic blood pressure during the previous 24 months may determine a higher 
risk of having a ﬁ rst HF hospital admission episode. 
 Keywords:  Heart failure ,  hospital admission ,  primary care ,  cardiovascular risk factors 
KEY MESSAGE:
 Since most patients at high cardiovascular risk are attended in primary care, the role of general practitioners  •
is crucial in preventing the development of heart failure. 
 Control of cardiovascular risk factors has shown to be determinant to prevent a ﬁ rst heart failure hospitalization.  •
 The relationship between several cardiovascular risk 
factors (CVRF) such as hypertension, high blood choles-
terol, diabetes, obesity, and smoking and HF incidence 
has been well-established (5 – 8). It has also been shown 
that minor reductions in the prevalence of some CVRF 
can decrease HF incidence (9). Nevertheless, prior to the 
publication of the 2009 ARIC Study there was insuﬃ  cient 
evidence concerning the impact of CVRF control on HF 
incidence. 
 While adequate CVRF management has been 
reported to result in lower HF incidence, most studies 
have only measured them at the commencement of the 
cohort follow-up, without considering an intermediate 
analysis (10). In addition, the optimum high-risk cut-oﬀ  
remains to be determined. 
 Although several cohort studies have analysed the 
eﬀ ect of CVRF in a long-term follow-up, little is known 
about the control of these factors prior to onset, par-
ticularly at the period close to the HF episode. This study 
aimed to determine the eﬀ ect of good CVRF control on 
the occurrence of ﬁ rst episode HF hospitalization. 
 METHODS 
 Study design 
 A retrospective, observational study was carried out com-
paring two groups, one with and the other without HF. 
Information used in the analysis came from a database 
located at the Heart Failure Unit of the Hospital del Mar, 
which covers the catchment area of the study (to identify 
the cases), and the SIDIAP (system information for the 
development of research in primary care) for the controls. 
The SIDIAP is a clinical database of anonymized patient 
records containing information for almost six million peo-
ple coming from 274 primary care practices in Catalonia. 
 Since a number of factors, such as variability in the 
quality of the primary healthcare record registration, 
could have inﬂ uenced the eﬀ ect of CVRF control on HF 
occurrence, we designed a case-control study using pro-
pensity score-matching methodology. This allowed us to 
assemble two balanced groups of patients sharing the 
same co-variable proﬁ le, with the exception of those of 
interest, in order to minimize the eﬀ ect of potential 
bias (11) (Figure 1 ). 
 All CVRF measurements obtained in a primary care 
setting during the two years prior to the ﬁ rst HF hospital 
admission were analysed. Four controls were taken for 
every case. Time was divided as follows: 24 to 13 months 
prior to the ﬁ rst HF episode; from 12 months to the day 
of the ﬁ rst HF episode; and the whole period of 
24 months prior to the HF episode. 
 Study population and inclusion criteria 
 Primary healthcare in this area is provided by 10 large 
centres with 168 general practitioners (GPs). All the 
centres share the same information technology system 
for recording clinical information electronically. Hospital 
reports are also available from this system and can be 
consulted by GPs. Clinical and laboratory test data 
corresponding to the two years prior to study inclusion 
were drawn from the primary healthcare records of all 
participants. 
 Cases. All patients were admitted because of a ﬁ rst HF 
episode between 2008 and 2011 to a hospital covering 
a population of 176 659 inhabitants living in Barcelona 
(Spain). The diagnoses were retrieved from the hospital 
discharge reports, which included the International Clas-
siﬁ cation of Diseases (ICD 9: 428). 
 Controls. Initially, the whole adult population     30 years 
old residing in the catchment area was selected, who 
had consulted their GP in the study period, and who 
were free from HF on the date of inclusion (ICD 10: I50). 
ICD 10 was employed because it is the classiﬁ cation sys-
tem used in primary healthcare records in Catalonia. 
 Matching process . Groups were paired by age, gender, 
CVRF, treatment for cardiovascular prevention, and the 
presence of coronary heart disease. 
 The process was carried out with the  ‘ nearest 
neighbour (calliper    0.2), ’  ‘ MatchIt ’ procedure, which 
improved the quality of matching (12,13). R Statistical 
package was used to analyse the results (14). Because of 
the high number of available controls, it was possible to 
achieve a very similar co-variable distribution in both 
groups. As a result, no more than one control for each 
case was needed to have statistical power to test the 
main hypothesis. 
 Figure 1. Follow-up chart showing the enrolment period of all 
participants according to inclusion date. 
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 Variables 
 The day of the incident HF episode was proposed as the 
date of study inclusion for both cases and matched con-
trols. Incident HF was deﬁ ned as a ﬁ rst hospitalization 
that, on the discharge report, included ICD 9: 428 as a 
ﬁ rst diagnosis since ICD 9 is the classiﬁ cation system 
used by hospitals. For each matched potential control, 
information was collected according to the date of hos-
pital admission of the respective case. This procedure 
allowed us to obtain the same period of analysis for 
cases and controls. 
 Variables used for the matching procedures. Cases and 
controls were paired for multiple variables that could 
inﬂ uence the eﬀ ect of CVRF on HF occurrence. In addi-
tion to socio-demographic variables (gender and age), 
the following were included in the matching process: 
 Cardiovascular co-morbidity: hypertension (ICD 10:  •
I10 – I15), dyslipidaemia (ICD10: E78), coronary heart 
disease (ICD 10: I20 – I25), stroke (ICD 10: I61, I63, 
I64), and diabetes mellitus (ICD 10: E10 – E14). 
 Drug therapy for CVRF: angiotensin-converting  •
enzyme inhibitors, angiotensin-receptor blocker, 
dosazoxine, statins, diuretics, calcium channel 
blockers, beta-blockers, aspirin, and glucose-lowering 
drugs. 
 Independent variables considered for analysing the eﬀ ect 
of CVRF control on HF occurrence. Values for systolic and 
diastolic blood pressure, total cholesterol, LDL and HDL 
cholesterol, heart rate, creatinine, fasting blood glucose, 
triglycerides, glycosylated haemoglobin, and body mass 
index were also gathered from medical records. For the 
purpose of the analysis, measurements were summa-
rized in three groups: the mean of all variable measure-
ments taken the year prior to the inclusion date; the 
mean of all variable measurements taken in the period 
24 to 13 months prior to inclusion; and, and the mean 
of the whole period (the two years) prior to the inclusion 
date. 
 In 2013, European guidelines set a goal to achieve 
blood pressure levels below 150 – 140/90 mmHg (15). Lip-
ids were considered well controlled when LDL-cholesterol 
was lower than 115 mg/dl and glucose control when 
glycosylated haemoglobin was lower than 7% (16). 
 Statistical analysis 
 An initial, descriptive comparison between groups of all 
variables was performed to evaluate their balance after 
the matching process. Statistical signiﬁ cance was 
assessed by the chi-square test when the frequencies of 
comorbidity and demographic variables were compared 
among groups. The average determinations between 
one year and two years prior to the inclusion date were 
compared by student ’ s  t -test. This analysis was con-
ducted with complete cases (Tables 1 and 2). 
 Diﬀ erent logistic regression models (ENTER method) 
were developed to analyse the relationship among the 
values of previous determinations of risk factors and the 
occurrence of HF. Models were adjusted by variables 
that were statistically signiﬁ cant at bivariate analysis or 
were clinically associated with HF. In all models, the 
goodness of ﬁ t hypothesis was tested by the Hosmer –
 Lemeshow test. 
 Multiple imputation procedure was used to handle 
missing data in the multivariate analysis using Stata 12 
(Stata Statstical Software: Release 12; StataCorp LP, 
College Station, TX). The estimates of the parameters for 
each imputed data set were combined using Rubin ’ s 
rules. Estimates of the risk diﬀ erences and odds ratios 
are reported with corresponding 95% conﬁ dence inter-
vals and  P values. In all tests, a level     0.05 was consid-
ered statistically signiﬁ cant. 
 Ethics 
 All Helsinki Declaration ethical criteria were respected. 
Since it was an observational study, participants 
underwent no interventions other than the usual clinical 
care. Information from clinical records was correctly 
anonymized before analysis in order to preserve partici-
pants ’ conﬁ dentiality. The study protocol was approved 
by the Primary Healthcare University Research Institute 
IDIAP-Jordi Gol. 
 RESULTS 
 From the potentially eligible 152 cases and 176 090 
controls, 645 participants were ﬁ nally selected (129 
cases and 516 controls) after the matching process, 
which reduced the probability of a selection bias by 98% 
(Figure 2). 
 Table 1. Diﬀ erences in cardiovascular comorbidity between individuals 
admitted to hospital because of a ﬁ rst heart failure episode and those 
without heart failure, after the matching process. 
Cases 
(heart failure) 
 n    129 
 n (%)
Controls (free 
from heart failure) 
 n    516 
 n (%)  P value 
Comorbidity
Smoker 20 (15.5) 58 (11.2) 0.184 
Dyslipidaemia 57 (44.2) 230 (44.6) 0.937 
Hypertension 87 (67.4) 363 (70.3) 0.52 
Coronary heart 
disease
23 (17.8) 72 (14.0) 0.267 
Diabetes 47 (36.4) 215 (41.7) 0.279 
Stroke 11 (8.5) 47 (9.1) 0.836 
Sex
Male 68 (52.7) 268 (51.9) 0.875 
Female 61 (47.3) 248 (48.1)
 SD, standard deviation. 
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by hypercholesterolaemia (44.5%), type 2 diabetes 
(40.6%), and smoking (12.1%). Since the two groups 
were paired for all these factors, diﬀ erences between 
them after the matching process were not signiﬁ cant. 
Mean age was 71.9 (SD: 11.2) in the group of cases and 
73.4 (SD: 11.9) in the control group ( P    0.187). Other 
variables are presented in Table 1. 
 With respect to the number of CVRF present at inclu-
sion, 84.7% had at least one CVRF, and 57.5% had two 
or more. There were no diﬀ erences between cases and 
controls with respect to the number of CVRF present at 
inclusion ( P trend    0.474). 
 Cardiovascular risk factors 
 Regarding the time elapsed before the ﬁ rst HF episode, 
body mass index was found to be signiﬁ cantly higher 
in both the previous one and two years (Table 2). Sys-
tolic blood pressure was higher during the whole 
period, particularly in the 12 months prior to the ﬁ rst 
HF episode. Blood pressure control (systolic blood 
pressure     140 mmHg and/or diastolic blood pres-
sure     90 mmHg) was worse during the whole study 
period without reaching a statistical signiﬁ cance. Fast-
ing blood glucose levels appeared to be related to HF 
occurrence. Total cholesterol and low-density lipopro-
tein cholesterol did not show statistical diﬀ erences 
between cases and controls although high-density lipo-
protein cholesterol levels were signiﬁ cantly lower in 
the former. 
 Population characteristics 
 The average age was 73.0 (SD: 11.8) years, and 47. 9 % 
were women. Among cases, 49.6% had HF with pre-
served ejection fraction. The most frequent CVRF pres-
ent in both groups was hypertension (69.8%), followed 
 Table 2. Diﬀ erences in cardiovascular risk factor levels and their control between individuals admitted to hospital because of a ﬁ rst heart failure 
episode (cases) and those free from heart failure (controls), according to the time elapsed before the date of inclusion. (The inclusion date was 
determined by the hospital admission of the corresponding cases.). 
Last 12 months before 
the date of inclusion
Between 24 and 13 months before 
the date of inclusion
Cases 
(heart failure episode)
 n    129
Controls 
(free from heart failure)
 n    516
Cases 
(heart failure episode)
 n    129
Controls 
(free from heart failure)
 n    516
Variable Mean SD Mean SD  P value Mean SD Mean SD  P value 
Body mass index 33.0 6.2 29.8 5.4 0.001 33.4 6.9 30.0 5.1    0.001 
Heart rate 76.1 10.9 73.6 11.6 0.133 74.9 11.8 73.0 10.9 0.279 
Systolic blood pressure 142.2 20.6 135.4 14.4 0.001 138.6 17.8 136.7 16.3 0.413 
Diastolic blood pressure 76.2 10.0 73.0 8.9 0.009 75.9 8.0 74.6 9.2 0.331 
Blood pressure 
uncontrolled (%) a 
44.0% 34.0% 0.12 45.6% 42.9% 0.713
Glycosylated haemoglobin 7.3 1.6 6.9 1.3 0.173 7.3 2.1 6.5 1.2 0.011 
Glycosylated 
haemoglobin    7 (%)
58.0% 36.5% 0.029 38.1% 24.7% 0.209
Fasting blood glucose 133.6 53.3 128.7 41.4 0.491 153.9 58.0 125.2 33.3    0.001 
Total cholesterol 186.8 42.8 198.2 39.9 0.059 191.7 43.0 199.0 40.2 0.322 
HDL cholesterol 46.5 10.5 52.7 14.0 0.004 47.0 12.5 53.8 14.3 0.016 
LDL cholesterol 114.7 33.9 120.8 33.7 0.264 111.0 35.0 121.1 34.3 0.154 
Lipids uncontrolled (%) 
LDL    115)
50.0% 52.7% 0.734 39.3% 54.6% 0.131
Triglycerides 145.2 71.8 128.2 58.6 0.072 197.8 150.8 126.9 61.7    0.001 
Renal function (creatinine) 1.0 0.3 1.0 0.4 0.246 1.0 0.3 1.0 0.3 0.406 
 HDL, high density lipoprotein; LDL, low density lipoprotein. 
 a Systolic blood pressure    140 and/or diastolic blood pressure    90 mmHg. 
 Figure 2. Flow chart showing the participants ’ selection process. 
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of cardiovascular diseases and help prevent HF develop-
ment (18). However, the extent to which these levels 
must be lowered to achieve maximum beneﬁ t remains 
controversial (15). A community based cohort study 
found a continuous positive association between systolic 
blood pressure and HF risk in the elderly for levels as low 
as 115 mmHg (19). Nevertheless, a recent meta-analysis 
did not observe any beneﬁ ts in reaching blood pressure 
levels below 150/80 mmHg (20). Regarding the elderly, 
two Japanese studies reported that reductions of systolic 
blood pressure under 142 mmHg did not add any ben-
eﬁ t to cardiovascular risk (21,22). 
 The results are in accordance with those recommend-
ing a more exhaustive blood pressure control (19). 
 Body mass index 
 In concurrence with other studies, a greater proportion 
of HF in both subjects with a higher body mass index and 
individuals with worse fasting blood glucose levels was 
observed (23 – 25). However, and in contrast to some 
other studies, we did not ﬁ nd a higher frequency of HF 
in diabetic patients with poorly controlled glycosylated 
haemoglobin, which may have been due to our small 
sample size (26). 
 With respect to cholesterol and in agreement with a 
review published by Kannel in 2000, no relationship was 
observed between total cholesterol and a higher occur-
rence of HF (3). 
 Strengths and limitations 
 The cases included in the study, had a validated HF diag-
nosis based on discharge reports. More than 170 000 
potential controls (all living in the area and complying 
with the inclusion criteria) were initially retrieved from 
 When analysing all blood pressure measurements 
taken during the whole period of the study, it was found 
that 11.0% (mean 2.03) and 6. 0 % (mean 1.2) of the 
total ( P    0.001) were badly controlled in cases and 
controls, respectively. No diﬀ erences were found 
between cases and controls regarding the percentage 
of well-controlled glycosylated haemoglobin and LDL 
measurements. 
 Multivariable analysis, after adjusting for potential 
confounding factors, showed that the probability of hav-
ing an HF episode when systolic blood pressure was 
greater during the year immediately before diagnosis 
(OR: 1.03 95% CI: 1.01 – 1.04) (Table 3). 
 DISCUSSION 
 Main ﬁ ndings 
 In this study was found that even moderately increased 
levels of body mass index and systolic blood pressure 
determined a higher risk of having a ﬁ rst HF episode. This 
risk was especially signiﬁ cant in the case of systolic blood 
pressure where the possibility of experiencing an HF was 
1.3 times higher for every 5 mmHg increment during the 
year prior to the ﬁ rst HF hospitalization episode. Although 
fasting blood glucose tended to be high in all HF patients, 
when diabetic patients were considered separately gly-
cosylated haemoglobin did not aﬀ ect the risk. Regarding 
lipid proﬁ le, only high-density lipoproteins were related 
to HF occurrence. 
 Hypertension 
 Hypertension is the principal risk factor involved in HF 
occurrence (17). Aggressive lowering of blood pressure 
has been reported to play a key role in reducing the risk 
 Table 3. Crude and adjusted odds ratio for the ﬁ rst heart failure hospital admission episode according to previous clinical determinations. ORs have 
been calculated according to the variation for each unit of the corresponding variables. 
Variable OR adjusted 95% CI  P value OR crude 95% CI  P value 
Time: 12 months before heart failure episode
Body mass index (kg/m 2 ) 1.06 (0.99 – 1.13) 0.072 1.09 (1.03 – 1.15) 0.005 
Heart rate (beat/min) 1.02 (1.00 – 1.05) 0.074 1.02 (1.00 – 1.05) 0.055 
Systolic blood pressure (mm/Hg) 1.03 (1.01 – 1.04) 0.006 1.03 (1.01 – 1.04)    0.001 
Diastolic blood pressure (mm/Hg) 1.02 (0.98 – 1.05) 0.351 1.04 (1.01 – 1.07) 0.002 
HDL cholesterol (mg/dl) 0.95 (0.92 – 0.98) 0.005 0.95 (0.92 – 0.98) 0.001 
LDL cholesterol (mg/dl) 1.00 (0.99 – 1.01) 0.469 0.99 (0.99 – 1.00) 0.226 
Time: between 24 and 13 months before 
heart failure episode
Body mass index (kg/m 2 ) 1.08 (1.01 – 1.15) 0.022 1.09 (1.04 – 1.16) 0.001 
Heart rate (beat/min) 1.02 (0.99 – 1.05) 0.159 1.02 (1.00 – 1.05) 0.086 
Systolic blood pressure (mm/Hg) 1.01 (0.99 – 1.03) 0.274 1.01 (0.99 – 1.03) 0.263 
Diastolic blood pressure (mm/Hg) 1.00 (0.97 – 1.04) 0.798 1.02 (1.00 – 1.05) 0.1 
HDL cholesterol (mg/dl) 0.97 (0.94 – 1.00) 0.064 0.97 (0.94 – 1.00) 0.028 
LDL cholesterol (mg/dl) 1.00 (0.99 – 1.01) 0.578 0.99 (0.99 – 1.00) 0.280 
 OR adjusted, odds ratio adjusted by logistic model by presented variables; OR crude, odds ratio without adjustment; 95% CI, 95% conﬁ dence interval; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein 
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 Implications for clinical practice 
 These results should encourage GPs to ﬁ ll the preventive 
gap that occurs with many patients due to their not dis-
playing a high-risk proﬁ le. The results indicate the rele-
vance of sustained, well-controlled CVRF. Moreover, we 
would like to stress that the continuity and longitudinal-
ity of care provided by primary healthcare professionals 
are crucial in order to prevent a ﬁ rst episode of HF in a 
population at risk. 
 Conclusion 
 Increased levels of body mass index and systolic blood 
pressure during the previous 24 months may determine 
a higher risk of having a ﬁ rst HF hospitalization 
episode. 
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